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Inhibitors of aromatase prevent degradation of the
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Summary The effects of two steroidal (4-hydroxyandrostenedione and atamestane) and three non-steroidal (fadrozole, vorozole and
pentrozole) aromatase inhibitors on the levels of aromatase mRNA and protein were examined using cultured JEG-3 and HepG2 cells.
Immunocytochemical studies demonstrated increased quantities of immunoreactive aromatase in both cell types as a result of these
treatments. To clarify this effect in detail, quantitation of aromatase protein in JEG-3 cells was performed after various treatments using
an enzyme-linked immunosorbent assay. Time-dependent increase was observed with all the aromatase inhibitors except 4-
hydroxyandrostenedione. The three non-steroidal agents caused an approximately fourfold elevation in the cells 24 h after the treatment
compared with untreated controls. The inhibitors also appeared to block the rapid degradation observed in JEG-3 cells after induction with
forskolin. However, aromatase mRNA levels in JEG-3 cells remained unchanged. Furthermore, the increase in aromatase protein in JEG-3
cells due to the inhibitor action was not blocked by treatment with cycloheximide, an inhibitor of protein synthesis. These results thus suggest
that aromatase inhibitors increase aromatase protein through stabilization and reduced protein turnover as a side-effect of their binding.
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Aromatase catalyses a rate-limiting step ofaromatization ofandro-
gens in oestrogen biosynthesis and is known to play an important
role through oestrogen production in various physiological func-
tions. This enzyme has been shown to be present in breast (Abul-
Hajj et al, 1979; Santner et al, 1984; Miller and O'Neill, 1987) and
endometrial cancer tissues (Noble et al, 1996) as well as various
gonadal and extragonadal tissues. In the case of breast cancer,
aromatase protein and mRNA were reported to be localized in
adipose stromal cells proximal to tumours (Bulun et al, 1993;
Santen et al, 1994; Sasano et al, 1994; Harada et al, 1995) and intra-
tumoral stromal cells (Esteban et al, 1992; Lu et al, 1996).
Oestrogens are known to function as mitogenic factors in certain
tissues, suggesting that local production ofoestrogens by aromatase
may play an essential role in the pathogenesis of oestrogen-depen-
dent breast and endometrial cancers, maintaining proliferation in a
paracrine or autocrine fashion. Therefore, one approach to therapy
is to reduce or eliminate continuous stimulation by circulating and
locally produced oestrogens, and a number of aromatase inhibitors
capable of causing cancer regression in patients have been intro-
duced for such endocrine therapy (Brodie, 1994).
Aminoglutethimide is an agent initially finding clinical applica-
tion as a possible therapeutic aromatase inhibitor for breast cancer
patients (Santen and Misbin, 1981). However, it also inhibits
cholesterol side-chain cleavage reaction by P-450scc, resulting in a
deficiency ofglucocorticoids and mineralocorticoids as well as sex
steroids. 4-Hydroxyandrostenedione (4-OHA) was subsequently
identified as a potent and specific inhibitor (Marsh et al, 1985),
functioning as a mechanism-based inhibitor or a suicide substrate
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and causing time-dependent inactivation in the presence of co-
factors (Brodie et al, 1981). Recently, more potent and selective
non-steroidal inhibitors ofimidazole, triazole, and tetrazole deriva-
tives have been developed and clinically examined (Brodie, 1994).
Success in determining the three-dimensional structures of
cytochromes P-450CAM (Poulos et al, 1985) and P-450BM-3
(Ravichandran et al, 1993) using X-ray diffraction promoted studies
of structure-function relationships of aromatase using homology
molecularmodelling and site-directedmutagenesis (Graham Lorence
et al, 1991, 1995; Zhou et al, 1991; Chen and Zhou, 1992; Amarneh
et al, 1993). According to the proposed model, the relatively large
hydrophobic pocketofthe active site should allowbinding ofvarious
aromatase inhibitors with different sizes and structures.
There have been many reports concerning development and
clinical trials of new aromatase inhibitors for breast cancer
patients. Consequently, there is abundant information about their
effectiveness. However, the effects of aromatase inhibitors on
synthesis and degradation ofaromatase mRNA and protein remain
unclear. In this study, we therefore examined these parameters
in cultured cells. As it was essential for accuracy to use cells
expressing high levels of aromatase owing to the limited sensi-
tivity ofthe ELISA assay, JEG-3 and HepG2 cells were chosen for
this study from among the various tumour cell lines available. The
results suggested that aromatase inhibitors stabilize the enzyme in
the cells and prevent its degradation, probably through formation
oftightly associated aromatase/inhibitor complexes.
MATERIALS AND METHODS
Reagents
Atamestane (1-methyl-androsta-1,4-diene-3, 17-dione), 4-hydrox-
yandrostenedione, fadrozole (4-(5,6,7,8-tetrahydroimidazo-
[1,5a]-pyridine-5-yl)-benzonitrile monohydrochloride), vorozole
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Figure 1 Immunocytochemistry of aromatase in JEG-3 and HepG2 cells treated with aromatase inhibitors. JEG-3 (A-C) and HepG2 (D-F) cells were cultured
in the presence of 10 gM aromatase inhibitors at 370C for 24 h, and then the immunoreactive aromatase in the control (A and D), vorozole-treated (B and E),
and atamestane-treated (C and F) cells was observed by fluorescent microscope. Bars = 20 gm
(6-[(4-chlorophenyl)( 1H-1,2,4-triazol- 1-yl)methyl] 1-methyl-
1H-benzotriazole), and pentrozole (5-[cyclopentylidene-(1-
imidazolyl)-methyl]-thiophene-2-carbonitrile monohydrochlo-
ride), were kindly synthesized and provided by the laboratories of
Schering AG (Berlin, Germany). Biotin (long arm) NHS and
alkaline phosphatase streptavidin were obtained from Vector
Laboratories (Burlingame, CA, USA). Microtitre plates
(MaxiSorp) were purchased from Nunc (Roskilde, Denmark).
Cell culture
Human choriocarcinoma-derived JEG-3 and hepatoma-derived
HepG2 cells, obtained from American Type Culture Collection
(Bethesda, MD, USA) and Riken Cell Bank (Tsukuba, Japan),
respectively, were maintained in minimum essential medium
alpha-modification supplemented with 10% fetal calf serum at
37°C in a 95% air/5% carbon dioxide humidified atmosphere. To
assess the effects of the inhibitors on aromatase protein, the cells
were exposed to 10 gM aromatase inhibitors for 12, 24 or 48 h.
The contents of aromatase protein in the cells were determined by
ELISA. To confirm inhibition of cellular protein synthesis by
cycloheximide, incorporation of L-[4,5-3H]leucine into aromatase
in JEG-3 cells was examined, as described previously (Harada and
Omura, 1983).
Preparation of total RNA and microsomal fractions
from cultured cells
After washing with Dulbecco's phosphate-buffered saline (PBS),
cells were scraped from culture dishes and homogenized with
0.25 M sucrose containing 10 mM Tris-HCl (pH 7.5) and 1 mM
EDTA. Microsomal fractions were prepared by successive
centrifugation (Harada and Omura, 1980). Total RNA fractions
were isolated from cells using the Trizol reagent (Gibco-BRL,
Gaithersburg, MD, USA) according to the manufacturer's instruc-
tions and suspended in 10mM Tris-HCl (pH 7.5) containing 1 mM
EDTA and 0.05 units ml-' ofribonuclease inhibitor (Inhibit-ACE;
SPrime-3Prime, Boulder, CO, USA).
Aromatase immunocytochemical staining
A rabbit polyclonal anti-human aromatase antibody was prepared
against the enzyme purified from human placenta (Harada, 1988).
This antibody has been confirmed to be monospecific using
biochemical and immunological tests (Harada, 1988) and been
validated for the detection of aromatase by immunocytochemical
staining (Naganuma et al, 1990). Furthermore, the immunospeci-
ficity of the antibody was demonstrated by Western blotting
analysis of aromatase in JEG-3 cells treated or untreated with
aromatase inhibitors, which showed only a single protein band
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Figure 2 Time-course of increase of aromatase protein in JEG-3 cells
treated with various aromatase inhibitors. JEG-3 cells were cultured in the
absence (0) or presence of 10gM 4-OHA (0), atamestane (A), pentrozole
(A), vorozole (0), or fadrozole (M) at 370C. The cells were collected 12, 24
and 48 h after the addition of aromatase inhibitors, and the contents of
aromatase protein in the cells were determined by ELISA. Results are the
means ± s.e.m. of three experiments. *P < 0.05 compared with the respective
control values
Table 1 Effects of aromatase inhibitors on aromatase protein levels in
JEG-3 cells
Treatment Aromatase content
(ng mg1 of microsomal protein)
Before forskolin stimulation 10.2 ± 0.9
Forskolin stimulation for 48 h 121.5 ± 5.1
24 h after removal of forskolin
Control 55.7 ± 1.7
Atamestane 99.6 ± 6.9*
4-OHA 58.9 ± 2.8
Fadrozole 202.1 ± 9.3*
Vorozole 192.4± 7.8*
Pentrozole 196.1 ± 9.1*
Forskolin was given to JEG-3 cells at 10gM to induce aromatase. After
pretreatment for 48 h, the cells were washed with PBS to completely remove
the forskolin and then further cultured for 24 h without forskolin in the
presence of 10gM aromatase inhibitors or in the absence of the inhibitors as
a control. Results are the means ± s.e.m. of three experiments. *P< 0.05
compared with the control.
with the molecular size corresponding to human aromatase. The
immunocytochemical procedures used have been described
previously (Hatano et al, 1994). Immunocytochemical staining of
aromatase was carried out using rabbit anti-human aromatase and
FITC-labelled donkey anti-rabbit immunoglobulin antibodies as
primary and secondary antibodies respectively.
Enzyme-linked immunosorbent assay (ELISA)
The rabbit polyclonal anti-human aromatase antibodies (15 mg)
were conjugated with 8 gmol of biotin (long arm) NHS. We first
determined optimal conditions for ELISA. High concentrations of
detergent and glycerol were found to be significantly inhibitory for
the immunological reaction and a high concentration of proteins
disturbed the accuracy of quantitation. Microsomal fractions
(0.5 mg ml-1) were solubilized with 50 mi Tris-HCl (pH 8.0)
containing 0.15 M NaCl, 0.1% Tween 20, 0.2% sodiumcholate and
then centrifuged at 105 000 xg for 90 min to obtain the solubilized
supernatants. Microtitre wells were precoated with 2 ig ml-' anti-
aromatase antibody at 37°C for 2 h. After washing with PBS,
blocking with PBS containing 1% BSA at room temperature for
30 min, and again washing with PBS, 200-gl aliquots ofthe solu-
bilized supernatants of microsomal fractions were added to the
wells and incubated at room temperature for 2 h. Wells for blanks
and aromatase standards were also included with the addition of
serial dilutions (0-S50 ng ml-') of purified human aromatase in
place of solubilized supematant. After washing with PBS, 200 pl
of biotin-labelled anti-aromatase antibody (5 ,ug ml-' in PBS
containing 1% BSA) was added to each well, followed by incuba-
tion at room temperature for 1 h. After washing with PBS, 200 gl
of alkaline phosphatase-streptavidin was added to each well, and
incubated for 30 min. After washing with PBS, 200gl aliquots
of 2 mg ml-1 p-nitrophenylphosphate in 0.1M diethanolamine
(pH 9.8) containing 1 mm magnesium chloride were added to the
wells. Afterfurther incubation for40 min in the dark, the reactions
were stopped by adding 50gl of 2 M sodium hydroxide. The
absorbance was measured at 405 nm on a Microplate Reader
MTP-32 (Corona Electric, Katsuta, Japan). Protein concentrations
were determined with a BCA protein assay kit (Pierce, Rockford,
IL, USA) using BSA as a standard.
Quantitative analysis of aromatase mRNA
The aromatase mRNA levels in total RNA fractions were fluoro-
metrically determined by reverse transcription-polymerase chain
reaction (RT-PCR) using a fluorescent dye, FAM-labeled primer
(Perkin Elmer, Foster City, CA, USA) in the presence of an
internal standard RNA, as previously described (Harada et al,
1995; Utsumi et al, 1996). The sequence between PCRprimer sites
is interrupted by two introns in human aromatase gene. The
internal standard RNA was synthesized with T7 RNA polymerase
using modified human aromatase cDNA, which was constructed
by inserting a 21-bp fragment ofHaeIII-digested X-DNA between
PCR primer sites, as a template. The fluorescent RT-PCR products
were analysed on a 2% agarose gel with a Gene Scanner 362 fluo-
rescent fragment analyser (Perkin-Elmer, Foster City, CA, USA).
The amount of aromatase mRNA in the total RNA was calculated
from the peak areas of the fluorescent products by the internal
standard method.
Statistical analysis
Statistical analysis was performed using one-way analysis of
variance (ANOVA), followed by the Scheffe test. A P-value
< 0.05 was considered to be significant.
RESULTS
Immunocytochemical analysis in aromatase
inhibitor-treated cells
Changes in the protein levels of aromatase in human chorio-
carcinoma-derived JEG-3 and hepatoma-derived HepG2 cells by
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Table 2 Effects of aromatase inhibitors on the levels of aromatase mRNA in
JEG-3 cells
Treatment Aromatase mRNA
(10-18 mol ,g-1 of total RNA)
Control (untreated) 6.07 ± 0.32
Control (forskolin) 51.72 ± 1.16
Atamestane 6.31 ± 0.20
4-OHA 5.98 ± 0.05
Fadrozole 6.04 ± 0.15
Vorozole 5.95 ± 0.19
Pentrozole 6.14 ± 0.24
Forskolin was given to JEG-3 cells at 10 gm to induce aromatase mRNA as a
positive control. Results are the means ± s.e.m. of three expenments.
Table 3 Effects of cycloheximide on the increase of aromatase protein in
JEG-3 cells caused by aromatase inhibitors
Treatment Aromatase content
(ng mg-1 of microsomal protein)
Control (untreated) 4.24 ± 0.41
Atamestane 7.16 ± 0.98
4-OHA 4.41 ± 0.31
Fadrozole 13.57 ± 0.95*
Vorozole 12.73 ± 0.80*
Pentrozole 14.61 ± 1.13*
JEG-3 cells were cultured in the presence of 20 9g ml-' cycloheximide
together with 10 gM aromatase inhibitors at 370C for 24 h. Results are the
means ± s.e.m. of three experiments. *P< 0.05 compared with the control.
treatment of aromatase inhibitors were first examined using
immunocytochemical staining. As shown in Figure 1, vorozole, a
non-steroidal aromatase inhibitor, markedly increased immuno-
reactive aromatase protein in both JEG-3 (B) and HepG2 (E) cells,
compared with untreated controls (A and D). Only a slight
increase in aromatase protein was observed with atamestane, a
steroidal aromatase inhibitor (C and F). Similar increase in both
cells was observed with the other non-steroidal aromatase
inhibitors, fadrozole and pentrozole, whereas the steroidal
aromatase inhibitor, 4-OHA, hardly gave significant changes in
both cells (data not shown).
Time-dependent changes of aromatase protein levels in
aromatase inhibitor-treated JEG-3 cells
To quantitatively investigate the increase in aromatase protein in
JEG-3 cells by aromatase inhibitors, an ELISA was developed and
checked for its specificity and quantitativeness. As shown in
Figure 2, although aromatase protein in untreated control cells
remained practically unchanged during the 48-h observation
period, all of the non-steroidal aromatase inhibitors, fadrozole,
vorozole and pentrozole, caused a time-dependent increase in
aromatase protein to about fourfold the control level after 24 h. In
contrast, although a time-dependent increase in aromatase protein
was also observed with the steroidal aromatase inhibitor
atamestane it was to a much lesserextent, and no significant effects
ofthe other steroidal aromatase inhibitor, 4-OHA, were noted.
Effects of aromatase inhibitors on decrease in
aromatase protein levels after forskolin induction in
JEG-3 cells
The effects of aromatase inhibitors on protein levels of aromatase
in JEG-3 cells were further investigated after the induction of
aromatase by forskolin. Aromatase was elevated about tenfold
(121.5 ± 5.1 ng mg-' microsomal protein) 48 h after the treatment
offorskolin. As shown in Table 1, the induced level was decreased
to about half24 h aftertheremoval offorskolin. This reduction was
not affected by 4-hydroxyandrostenedione treatment but was
prevented by atamestane. In contrast, the addition of the non-
steroidal aromatase inhibitors to the cells caused significant
increases in aromatase protein in spite ofthe absence ofthe inducer.
Effects of aromatase inhibitors on the levels of
aromatase mRNA in JEG-3 cells
The levels ofaromatase mRNA in JEG-3 cells treated with 10gM
aromatase inhibitors for 24 h were fluorometrically determined by
a quantitative RT-PCR method using an internal standard RNA
and a fluorescent dye-labelled primer. Table 2 summarizes the
results. The level of aromatase mRNA was increased approxi-
mately ninefold in the cells treated with forskolin as a positive
control, whereas no significant intergroup differences were
observed in the cells treated with aromatase inhibitors, indicating
that all ofthe inhibitors have no effects on the levels of aromatase
mRNA in the cells.
Effects of cycloheximide on the inhibitor-associated
increase of aromatase protein in JEG-3 cells
The results obtained in this study indicated thatthe higher levels of
aromatase protein in JEG-3 cells treated with aromatase inhibitors
was not due to increased mRNA levels, but rather to increased
translation or decreased degradation. To assess the first of these
possibilities, cycloheximide was simultaneously added as an
inhibitor of protein synthesis with aromatase inhibitors, and
changes in aromatase protein were again observed after 24 h. As
shown in Table 3, the levels of aromatase protein in the cells
treated with cycloheximide were all decreased compared with the
values without cycloheximide (Figure 2). However, all the non-
steroidal aromatase inhibitors still caused an approximately three-
fold increase, and atamestane also exerted some apparent effect.
4-Hydroxyandrostenedione, in contrast, did not cause any change
in the level ofaromataseprotein. As apositive control, [3H]leucine
incorporation into aromatase in the cells was also examined. It was
inhibited more than 95% by cycloheximide, indicating effective
suppression of protein synthesis in the cells by this dose of the
drug (data not shown). As essentially the same pattern ofincrease
in aromatase protein by aromatase inhibitors was observed with
and without cycloheximide, the results indicate that the elevation
of aromatase protein associated with aromatase inhibitors is
mediated by stabilization ofthe enzyme and prevention ofprotein
degradation.
DISCUSSION
In the present study, non-steroidal aromatase inhibitors, fadrozole,
vorozole, and pentrozole, clearly increased the immunoreactive
aromatase protein in cultured JEG-3 and HepG2 cells. Time
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dependence ofthe inhibitor influence was further demonstrated by
quantitative analysis using ELISA. The rapid degradation of
forskolin-induced aromatase followed by removal of the inducer
also appeared to be prevented by most of the inhibitors.
Presumably, they stabilized newly synthesized aromatase as well
as the forskolin-induced enzyme and, consequently, protein levels
in the cells were enhanced above the forskolin-stimulated level.
Additional evidence that the decrease in the turnover of enzyme
protein was responsible for the observed increase was provided by
the lack of apparent change in aromatase mRNA level and by the
fact that cycloheximide did not cause significant alteration of the
pattern of elevation. Thus, the results strongly suggest that
aromatase inhibitors exert their action on aromatase protein
through protection against protein degradation, ratherthan through
increase in transcription or translation, or mRNA stabilization. A
similar increase in aromatase protein in JEG-3 cells treated with
aminoglutethimide and fadrozole was also observed in another
laboratory (W Yue and AMH Brodie, personal communication).
Furthermore, Miller and Mullen (1993) showed that aromatase
activities in the tumours of breast cancer patients after aromatase
inhibitor (aminoglutethimide) treatment were significantly higher
than those of the same patients before the treatment. This result
supports the clinical significance ofour observation.
In the present study, we used aromatase inhibitors at the concen-
tration of 10gM. This is quite high compared with the minimum
concentration required to inhibit aromatase and also seems to be
high compared with those found in patients after clinical adminis-
tration of the inhibitors. Therefore, we performed additional
experiments to examine the effects of 1 and 0.1JIM inhibitor
concentrations on the levels of aromatase in JEG-3 cells and
obtained essentially similar results. The observed higher levels of
aromatase protein in the cells indicate that clinical doses of the
inhibitors might also generate higher levels of aromatase in
patients (data not shown). Increased dosage of such inhibitors
might be necessary to maintain complete suppression of cancer
cells, which otherwise might escape from aromatase inhibitor
control. Recently, anti-tumour hormone therapy with aromatase
inhibitors has been introduced for oestrogen-dependent cancers,
especially breast cancers. The data from clinical trials have
suggested that this may be an effective therapy without serious
harmful effects. However, it appears to be necessary to re-examine
further the possibility that aromatase inhibitor therapy could
induce a situation in which higher doses of inhibitors might be
required.
There are several possible explanations for the distinct differ-
ences in the effects ofthe various aromatase inhibitors used. First,
the capacities ofaromatase inhibitors to increase aromatase protein
in cells may reflect their binding affinities (Ki-values) for
aromatase. The K-values of 4-OHA and atamestane are reported
to be about 250 nm (Henderson et al, 1986), whereas those of
fadrozole and vorozole are 1.6 (Steele et al, 1987) and 0.7 nM
(Vanden Bossche et al, 1990) respectively. Judging from this
difference, non-steroidal inhibitors would be expected to be more
tightly associated with the aromatase molecules in stable
complexes that may be more resistant to proteolytic cleavage.
Second, steroidal aromatase inhibitors, 4-OHA and atamestane,
were known to be mechanism-based inhibitors or suicide
inhibitors (Brodie et al, 1981; Henderson et al, 1986). They
promote time-dependent inactivation of aromatase through
production of a reactive intermediate by the catalytically active
enzyme, and probably time-dependent degradation due to
increasing sensitivity of the inactive form to proteolytic cleavage.
It is likely that 4-OHA is a stronger mechanism-based inhibitor
than atamestane as their inactivation rates of aromatase are
reported to be 4.5 x 10-3 (Brodie et al, 1981) and 1.8 x 10-3 S-'
(Henderson et al, 1986) respectively. Consequently, this may be
the reason why 4-OHA did not cause an appreciable increase in
aromatase protein, in contrast to atamestane.
Aromatase inhibitors and substrates are thought to competi-
tively bind to the same binding sites within aromatase molecules
and to form conformationally tight complexes, so that they could
be expected to be resistant to proteolytic degradation. Stabilization
and increased content caused by substrates or inhibitors has been
found for many enzymes; for example the cellular levels of
arginase (Schimke, 1964) andtryptophan pyrrolase (Schimke et al,
1965) in rat liver are known to become elevated because of
decreased protein degradation dependent on the substrates arginine
and tryptophan. Furthermore, steroidogenic cytochrome P-4501,,
and aromatase could be successfully purified in the presence of
deoxycorticosterone (Takemori et al, 1975) and testosterone
(Harada, 1988) or androstenedione (Tan and Muto, 1986), used
as substrate stabilizers to prevent inactivation of the enzyme.
Recently, immunoreactive aromatase in quail brain was found
to be increased by the specific inhibitors fadrozole and
vorozole (Foidart et al, 1994). These results suggest that tight
aromatase/inhibitor complexes are also relatively resistant to
proteolytic degradation and, consequently, cause higher levels of
aromatase protein.
For the purposes ofthe present study, we developed ELISA for
quantitative analysis of aromatase protein in the cells. Kitawaki et
al (1989) previously introduced a similar method for quantitation
of catalytically active aromatase in human placenta, but the
content of aromatase in microsomes of JEG-3 cells is quite low
(about 10 ng mg-' of protein) compared with the placenta case
(about 15 ,ug mg-' of protein). Therefore, we solubilized micro-
somes with low concentrations of Tween 20 and sodium cholate
and performed ELISA in the absence of glycerol to avoid any
unnecessary interference with the immunological reaction. Under
these conditions, protein recovery was improved and accurate
quantitation could be confirmed. The aromatase was the more
stable P-420 form (Omura and Sato, 1964) that is catalytically
inactive.
The results obtained in this study support a conclusion that
blockage of aromatase degradation by inhibitors results in marked
increase in immunoreactive protein in cells in culture.
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